Genetics and Epigenetics of Parkinson's Disease

In 1997 a mutation in the a-synuclein (SNCA) gene was associated with familial autosomal dominant Parkinson's disease (PD). Since then, several loci (PARK1-15) and genes have been linked to familial forms of the disease. There is now sufficient evidence that six of the so far identified genes at PARK loci (a-synuclein, leucine-rich repeat kinase 2, parkin, PTEN-induced putative kinase 1, DJ-1, and ATP13A2) cause inherited forms of typical PD or parkinsonian syndromes. Other genes at non-PARK loci (MAPT, SCA1, SCA2, spatacsin, POLG1) cause syndromes with parkinsonism as one of the symptoms. The majority of PD cases are however sporadic “idiopathic” forms, and the recent application of genome-wide screening revealed almost 20 genes that might contribute to disease risk. In addition, increasing evidence suggests that epigenetic mechanisms, such as DNA methylation, histone modifications, and small RNA-mediated mechanisms, could regulate the expression of PD-related genes.

[1]  Chuong B. Do,et al.  Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database , 2012, PLoS genetics.

[2]  Sonja W. Scholz,et al.  Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.

[3]  A. Kanthasamy,et al.  Environmental Neurotoxic Pesticide Increases Histone Acetylation to Promote Apoptosis in Dopaminergic Neuronal Cells: Relevance to Epigenetic Mechanisms of Neurodegeneration , 2010, Molecular Pharmacology.

[4]  N. Seki,et al.  CpG hypermethylation of the UCHL1 gene promoter is associated with pathogenesis and poor prognosis in renal cell carcinoma. , 2008, The Journal of urology.

[5]  J. Stockman Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease , 2011 .

[6]  P. Lockhart,et al.  DJ-1 mutations are a rare cause of recessively inherited early onset parkinsonism mediated by loss of protein function , 2004, Journal of Medical Genetics.

[7]  J. Minna,et al.  Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia , 2006, International journal of cancer.

[8]  A. Kanthasamy,et al.  Paraquat induces epigenetic changes by promoting histone acetylation in cell culture models of dopaminergic degeneration. , 2011, Neurotoxicology.

[9]  T. Outeiro,et al.  Epigenetics in neurodegeneration: A new layer of complexity , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[10]  J. Houwing-Duistermaat,et al.  Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. , 2001, American journal of human genetics.

[11]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[12]  T. Yen,et al.  The parkinsonian phenotype of spinocerebellar ataxia type 3 in a Taiwanese family. , 2004, Parkinsonism & related disorders.

[13]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[14]  Yusuke Nakamura,et al.  Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease , 2009, Nature Genetics.

[15]  R. Obeid,et al.  Biomarkers of folate and vitamin B12 status in cerebrospinal fluid , 2007, Clinical chemistry and laboratory medicine.

[16]  Zhuohua Zhang,et al.  Regulation of Intracellular Manganese Homeostasis by Kufor-Rakeb Syndrome-associated ATP13A2 Protein* , 2011, The Journal of Biological Chemistry.

[17]  C. Woods,et al.  Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36 , 2001, Journal of medical genetics.

[18]  Gaofeng Wang,et al.  Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. , 2008, American journal of human genetics.

[19]  M. Mancuso,et al.  POLG1-Related and other “Mitochondrial Parkinsonisms”: an Overview , 2011, Journal of Molecular Neuroscience.

[20]  James B. Mitchell,et al.  Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. , 2004, Cancer cell.

[21]  T. Maeda,et al.  Aging-associated alteration of subtelomeric methylation in Parkinson's disease. , 2009, The journals of gerontology. Series A, Biological sciences and medical sciences.

[22]  R. Youle,et al.  Parkin is recruited selectively to impaired mitochondria and promotes their autophagy , 2008, The Journal of cell biology.

[23]  M. Ban,et al.  Tau and α‐synuclein in susceptibility to, and dementia in, Parkinson's disease , 2007 .

[24]  R. Schiffmann,et al.  Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? , 2003, Molecular genetics and metabolism.

[25]  Jan Gründemann,et al.  Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase , 2006, Nature Genetics.

[26]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[27]  J. Kornhuber,et al.  Global DNA hypomethylation and DNA hypermethylation of the alpha synuclein promoter in females with anorexia nervosa , 2007, Molecular Psychiatry.

[28]  P. Lockhart,et al.  Parkin genetics: one model for Parkinson's disease. , 2004, Human molecular genetics.

[29]  Heidi Phillips,et al.  Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.

[30]  Aldo Quattrone,et al.  Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. , 2006, JAMA.

[31]  F. Coppedè,et al.  Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. , 2009, Mutation research.

[32]  S. Tsuji,et al.  CpG Demethylation Enhances Alpha-Synuclein Expression and Affects the Pathogenesis of Parkinson's Disease , 2010, PloS one.

[33]  D. Berg,et al.  Genetic variability in the SNCA gene influences α‐synuclein levels in the blood and brain , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  R. Nussbaum,et al.  Levels of alpha‐synuclein mRNA in sporadic Parkinson disease patients , 2006, Movement disorders : official journal of the Movement Disorder Society.

[35]  Simon C. Potter,et al.  A Two-Stage Meta-Analysis Identifies Several New Loci for Parkinson's Disease , 2011, PLoS genetics.

[36]  F. Binkofski,et al.  Clinical spectrum of Kufor‐Rakeb syndrome in the Chilean kindred with ATP13A2 mutations , 2010, Movement disorders : official journal of the Movement Disorder Society.

[37]  P. Riederer,et al.  Different methylation of the TNF-alpha promoter in cortex and substantia nigra: Implications for selective neuronal vulnerability , 2008, Neurobiology of Disease.

[38]  Y. Agid,et al.  Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism. , 1998, Human molecular genetics.

[39]  W. Oyen,et al.  FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome , 2009, Neurology.

[40]  N. Hattori,et al.  Genetic mutations and functions of PINK1. , 2011, Trends in pharmacological sciences.

[41]  A. Letai,et al.  Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release. , 2009, Human molecular genetics.

[42]  Yan-ling Zhang,et al.  HDAC6 regulates aggresome‐autophagy degradation pathway of α‐synuclein in response to MPP+‐induced stress , 2011, Journal of neurochemistry.

[43]  Angela C. Poole,et al.  The PINK1/Parkin pathway regulates mitochondrial morphology , 2008, Proceedings of the National Academy of Sciences.

[44]  Yu Kyeong Kim,et al.  Importance of low-range CAG expansion and CAA interruption in SCA2 Parkinsonism. , 2007, Archives of neurology.

[45]  Bao-Rong Zhang,et al.  Study of Methylation Levels of Parkin Gene Promoter in Parkinson's Disease Patients , 2011, The International journal of neuroscience.

[46]  Jun Yu,et al.  Epigenetic identification of ubiquitin carboxyl‐terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors , 2008, Hepatology.

[47]  Hansong Deng,et al.  The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila , 2008, Proceedings of the National Academy of Sciences.

[48]  W. Westbroek,et al.  Exploring the link between glucocerebrosidase mutations and parkinsonism. , 2011, Trends in molecular medicine.

[49]  A. Contestabile,et al.  Valproic Acid is Neuroprotective in the Rotenone Rat Model of Parkinson’s Disease: Involvement of α-Synuclein , 2010, Neurotoxicity Research.

[50]  A. Singleton,et al.  Early‐onset L‐dopa‐responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations , 2010, Movement disorders : official journal of the Movement Disorder Society.

[51]  A. Kanthasamy,et al.  α-Synuclein Negatively Regulates Protein Kinase Cδ Expression to Suppress Apoptosis in Dopaminergic Neurons by Reducing p300 Histone Acetyltransferase Activity , 2011, The Journal of Neuroscience.

[52]  Oliver Kaut,et al.  Methylation Regulates Alpha-Synuclein Expression and Is Decreased in Parkinson's Disease Patients' Brains , 2010, The Journal of Neuroscience.

[53]  R. Margis,et al.  Identification of blood microRNAs associated to Parkinsonĭs disease. , 2011, Journal of biotechnology.

[54]  J. Hardy,et al.  Genetic Analysis of Pathways to Parkinson Disease , 2010, Neuron.

[55]  Eden R Martin,et al.  Genome‐Wide Association Study Confirms SNPs in SNCA and the MAPT Region as Common Risk Factors for Parkinson Disease , 2010, Annals of human genetics.

[56]  M. Farrer,et al.  Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. , 2007, Parkinsonism & related disorders.

[57]  Mohamad Saad,et al.  Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies , 2011, The Lancet.

[58]  F. Coppedè One-Carbon Metabolism and Alzheimer’s Disease: Focus on Epigenetics , 2010, Current genomics.

[59]  V. Álvarez,et al.  FGF20 rs12720208 SNP and microRNA-433 variation: No association with Parkinson's disease in Spanish patients , 2010, Neuroscience Letters.

[60]  M. Goedert,et al.  Tau mutations in familial frontotemporal dementia. , 2000, Brain : a journal of neurology.

[61]  G. Hannon,et al.  A MicroRNA Feedback Circuit in Midbrain Dopamine Neurons , 2007, Science.

[62]  D. Elstein,et al.  Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. , 2006, Blood cells, molecules & diseases.

[63]  J. Schneider,et al.  Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease , 2011, Neuroscience.

[64]  K. Doheny,et al.  Genomewide association study for susceptibility genes contributing to familial Parkinson disease , 2009, Human Genetics.

[65]  A. Verkerk,et al.  Allelic imbalance of expression and epigenetic regulation within the alpha‐synuclein wild‐type and p.Ala53Thr alleles in Parkinson disease , 2010, Human mutation.

[66]  R. Lu,et al.  Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin‐induced damage , 2012, British journal of pharmacology.

[67]  E. Masliah,et al.  Alpha-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases. , 2011, The Journal of biological chemistry.

[68]  O. Combarros,et al.  Replication of MAPT and SNCA, but not PARK16‐18, as susceptibility genes for Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[69]  R. Hawkins,et al.  α‐Synuclein produces a long‐lasting increase in neurotransmitter release , 2004, The EMBO journal.

[70]  J. Schulz,et al.  Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. , 2005, Human molecular genetics.

[71]  M. Ronaghi,et al.  Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays. , 2008, American journal of human genetics.

[72]  H. Steinbusch,et al.  Epigenetic regulation in the pathophysiology of Alzheimer's disease , 2010, Progress in Neurobiology.

[73]  David W. Miller,et al.  DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. , 2011, Human molecular genetics.

[74]  R. Nass,et al.  Identification of gene expression changes in transgenic C. elegans overexpressing human α-synuclein , 2006, Neurobiology of Disease.

[75]  Ruben Abagyan,et al.  Sirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's Disease , 2007, Science.

[76]  Xavier Estivill,et al.  MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. , 2011, Human molecular genetics.

[77]  J. Im,et al.  Repression of α-synuclein expression and toxicity by microRNA-7 , 2009, Proceedings of the National Academy of Sciences.

[78]  K. Wada,et al.  GIGYF2 is present in endosomal compartments in the mammalian brains and enhances IGF‐1‐induced ERK1/2 activation , 2010, Journal of neurochemistry.

[79]  D. Berg,et al.  Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. , 2009, Human molecular genetics.

[80]  Wei Jiang,et al.  Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. , 2009, The Journal of clinical investigation.

[81]  R. Nussbaum,et al.  Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.

[82]  Jan Gründemann,et al.  Elevated α-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease , 2008, Nucleic acids research.

[83]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[84]  C. Lautier,et al.  Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. , 2008, American journal of human genetics.

[85]  V. Uversky,et al.  Nuclear Localization of α-Synuclein and Its Interaction with Histones† , 2003 .

[86]  S. Berger The complex language of chromatin regulation during transcription , 2007, Nature.

[87]  A. Kakita,et al.  Accumulation of histone deacetylase 6, an aggresome‐related protein, is specific to Lewy bodies and glial cytoplasmic inclusions , 2011, Neuropathology : official journal of the Japanese Society of Neuropathology.

[88]  J. Olzmann,et al.  Aggresome formation and neurodegenerative diseases: therapeutic implications. , 2008, Current medicinal chemistry.

[89]  J. Nutt,et al.  Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease , 2007, Annals of neurology.

[90]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[91]  R. Jiao,et al.  Drosophila Histone Deacetylase 6 Protects Dopaminergic Neurons against α-Synuclein Toxicity by Promoting Inclusion Formation , 2010, Molecular biology of the cell.

[92]  J. Parvin,et al.  Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. , 2006, Human molecular genetics.

[93]  U. Rüb,et al.  Spinocerebellar ataxia 2 (SCA2) , 2008, The Cerebellum.

[94]  Georg Auburger,et al.  The ubiquitin pathway in Parkinson's disease , 1998, Nature.

[95]  Lubo Zhang,et al.  Epigenetic mechanisms in developmental programming of adult disease. , 2011, Drug discovery today.

[96]  E. Sidransky,et al.  The Role of Glucocerebrosidase Mutations in Parkinson Disease and Lewy Body Disorders , 2010, Current neurology and neuroscience reports.

[97]  Epaminondas Doxakis,et al.  Post-transcriptional Regulation of α-Synuclein Expression by mir-7 and mir-153 , 2010, The Journal of Biological Chemistry.

[98]  M. Beal,et al.  Molecular insights into Parkinson's disease , 2011, F1000 medicine reports.

[99]  Johannes Kornhuber,et al.  DNA hypermethylation of the alpha synuclein promoter in patients with alcoholism , 2005, Neuroreport.

[100]  R. Nass,et al.  Global microRNA Expression Profiling of Caenorhabditis elegans Parkinson's Disease Models , 2010, Journal of Molecular Neuroscience.

[101]  Carlos A. Matos,et al.  Polyglutamine diseases: The special case of ataxin-3 and Machado–Joseph disease , 2011, Progress in Neurobiology.

[102]  Marc Cruts,et al.  Genetic Etiology of Parkinson Disease Associated with Mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 Genes: A Mutation Update , 2010, Human mutation.

[103]  Philippe Amouyel,et al.  α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[104]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[105]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[106]  N. Sokol,et al.  Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression , 2010, Nature.

[107]  A. Bentivoglio,et al.  Novel mutations in SPG11 cause hereditary spastic paraplegia associated with early‐onset levodopa‐responsive Parkinsonism , 2011, Movement disorders : official journal of the Movement Disorder Society.

[108]  M. Barrachina,et al.  DNA Methylation of Alzheimer Disease and Tauopathy-Related Genes in Postmortem Brain , 2009, Journal of neuropathology and experimental neurology.

[109]  U. Dillmann,et al.  Methylation status and neurodegenerative markers in Parkinson disease. , 2009, Clinical chemistry.

[110]  F. Gillardon,et al.  MicroRNA and proteome expression profiling in early‐symptomatic α‐synuclein(A30P)‐transgenic mice , 2008, Proteomics. Clinical applications.

[111]  J. Schneider,et al.  Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition , 2010, Brain Research.

[112]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[113]  P. Lansbury,et al.  The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect α-Synuclein Degradation and Parkinson's Disease Susceptibility , 2002, Cell.

[114]  M. Mehler,et al.  Advances in Epigenetics and Epigenomics for Neurodegenerative Diseases , 2011, Current neurology and neuroscience reports.